Pharma
-
Permission granted by Bayer
Bayer wins FDA nod for a new kind of blood thinner
Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention.
By Jacob Bell • Nov. 9, 2026 -
Getty Images / Adam Smigielski
Sponsored by Baker Tilly USState incentives for commercial-stage life sciences companies
Factor incentives into expansion plans early to improve site decisions, manage commitments and free capital for what comes next.
By Rich Croghan, Glenn Walsh and Gabriel Sermeno • Nov. 9, 2026 -
Explore the Trendline➔
National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
TrendlineAlzheimer's disease
Many companies hope to follow in the footsteps of Biogen, Eisai and Eli Lilly by developing new therapies for the debilitating disease, which affects tens of millions of people and costs healthcare systems hundreds of billions of dollars each year.
By BioPharma Dive staff -
Getty Images
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
The FDA is now investigating the risk of malignancy associated with Zolgensma and is “evaluating whether regulatory action is appropriate.”
By Jonathan Gardner • Updated Nov. 9, 2026 -
Courtesy of Sanofi
Sanofi stops development of Nurix-partnered immune drug
The decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.
By Delilah Alvarado • Nov. 4, 2026 -
Courtesy of Novo Nordisk
Obesity drugsNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts
The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
By Kristin Jensen • Nov. 4, 2026 -
Jim Vondruska / Stringer via Getty Images
Trump administrationBiopharma likely to climb higher after ‘blue wave,’ analysts say
Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have “bigger fish to fry” than drug pricing, analysts said.
By Jonathan Gardner • Nov. 4, 2026 -
Permission granted by Merck & Co.
Keytruda biosimilars are coming — but they face an uphill battle
A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
By Kelly Bilodeau • Nov. 2, 2026 -
Getty Images
Earnings roundup: AstraZeneca’s cost cuts, Alnylam’s slump and Regeneron’s resilience
AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears surrounding a top drug and investors rewarded Regeneron for a record quarter.
By Ben Fidler • Nov. 2, 2026 -
imaginima via Getty Images
Sponsored by CencoraBreaking the silos: What effective scenario modeling looks like in 2026 and beyond
Explore how integrated scenario modeling helps pharma leaders navigate pricing uncertainty and the complexity of global launches.
Nov. 2, 2026 -
Getty Images
This week in chartsThis week in charts: ESMO’s winners and losers
The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.
By Jonathan Gardner • Oct. 30, 2026 -
Getty Images
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.
By BioPharma Dive staff • Oct. 30, 2026 -
Courtesy of Genmab A/S
Genmab soars to record highs after cancer drug succeeds in key trial
The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.
By Delilah Alvarado • Oct. 29, 2026 -
Mario Tama / Getty via Getty Images
Obesity drugsLilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.
By Jonathan Gardner • Oct. 28, 2026 -
Getty Images
News roundupLilly shuffles business structure; Novartis writes off part of Avidity deal
Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
By BioPharma Dive staff • Oct. 28, 2026 -
Alamy
Obesity drugsCourt rejects Novo bid to block Lilly obesity drug ads
Novo failed to prove that Lilly’s campaign — which featured claims of obesity drug superiority — meaningfully harmed the Danish company’s sales, a federal judge ruled.
By Jonathan Gardner • Oct. 27, 2026 -
Sean Gallup via Getty Images
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
The companies said the findings suggest the treatment has a “limited” impact in HER2-low breast cancer, an area where AstraZeneca and Daiichi Sankyo’s Enhertu has already set a high bar.
By Delilah Alvarado • Oct. 26, 2026 -
Adobe Stock
Sponsored by Azurity PharmaceuticalsThe molecule was fine. The moment wasn’t.
Some overlooked medicines aren’t failures. They just arrived before the market was ready.
By Ron Scarboro, CEO, Azurity Pharmaceuticals • Oct. 26, 2026 -
Permission granted by Cytiva
Sponsored by CytivaNovel protein and peptide therapeutics
Explore manufacturing challenges and solutions for ADCs, bispecifics, peptides and more.
Oct. 26, 2026 -
Getty Images
This week in chartsThis week in charts: a big year for RNAi developers
The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.
By Delilah Alvarado • Oct. 23, 2026 -
Getty Images
Obesity drugsGLP-1 compounder issues recall for copycat Zepbound
The notice adds to growing concerns about the safety of knockoff weight loss drugs, which have remained popular despite FDA warnings and legal pressure from Eli Lilly and Novo.
By Jonathan Gardner • Oct. 22, 2026 -
Permission granted by Roche
Roche affirms sales outlook amid doubts about its future
Lower-than-expected sales of Xolair stood out as the Swiss drugmaker readies for an onslaught of generic competition for top products.
By Kristin Jensen • Oct. 22, 2026 -
Alamy
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
Hibsago is viewed as a potential “functional cure” for chronic infections and an important part of the British drugmaker’s goal of reaching £40 billion in annual revenue by 2031.
By Delilah Alvarado • Oct. 21, 2026 -
Getty Images
Hype vs. reality: What pharma’s hottest R&D bets have actually proved
New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.
By Sy Mukherjee • Oct. 20, 2026 -
Courtesy of Merck KGaA
Merck KGaA bets on RNAi with $1.3B Silence buyout
The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.
By Jonathan Gardner • Oct. 19, 2026 -
Commercial stock photo. Standard royalty-free license. Photographer: Simon Kadula
Sponsored by Thermo Fisher ScientificHow early should you engage a CDMO?
Discover which CMC activities can move forward early, and which decisions need to remain flexible.
By Kevin Kane, CMC Sciences Director, Clinical Research, Thermo Fisher Scientific • Oct. 19, 2026
